Bagsværd, Denmark, 22 January 2015 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity.
Saxenda®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation.The CHMP positive opinion recommends that Saxenda® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of >= 30 kg/m2(obese), or >= 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
For further information
|Mike Rulis||+45 3079 3573||[email protected]|
|Ken Inchausti (US)||+1 609 514 8316||[email protected]|
|Kasper Roseeuw Poulsen||+45 3079 4303||[email protected]|
|Jannick Lindegaard Denholt||+45 3079 8519||[email protected]|
|Melanie Raouzeos||+45 3075 3479||[email protected]|
|Daniel Bohsen||+45 3079 6376||[email protected]|
|Frank Daniel Mersebach (US)||+1 609 235 8567||[email protected]|
Company announcement No 4 / 2015